Celgene has been granted a patent for compounds and compositions that modulate S1P5 for treating neurological diseases. The patent claim includes a compound selection for this purpose. GlobalData’s report on Celgene gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Celgene Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Celgene, was a key innovation area identified from patents. Celgene's grant share as of February 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

The granted patent (Publication Number: US11919879B2) discloses a series of claims related to compounds and pharmaceutical compositions for the treatment of neurological diseases. The claims include the selection of specific compounds, pharmaceutical compositions comprising these compounds along with pharmaceutically acceptable excipients, and methods of treating neurological diseases in subjects in need. The neurological diseases specified for treatment in the claims are Alzheimer's disease or multiple sclerosis.

The patent claims cover a range of compounds and pharmaceutical compositions that can be used for treating neurological diseases, specifically Alzheimer's disease and multiple sclerosis. The methods outlined in the claims involve administering the compounds or their pharmaceutically acceptable salts to subjects in need of treatment. By specifying the neurological diseases targeted for treatment, the patent provides a clear focus on addressing conditions that have a significant impact on individuals. Overall, the patent offers a promising avenue for the development of treatments for neurological diseases, highlighting the potential for innovation and advancement in this critical area of healthcare.

To know more about GlobalData’s detailed insights on Celgene, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies